CN118436777A - 通过转换疗法治疗rms - Google Patents

通过转换疗法治疗rms Download PDF

Info

Publication number
CN118436777A
CN118436777A CN202410529206.7A CN202410529206A CN118436777A CN 118436777 A CN118436777 A CN 118436777A CN 202410529206 A CN202410529206 A CN 202410529206A CN 118436777 A CN118436777 A CN 118436777A
Authority
CN
China
Prior art keywords
ofatuzumab
disease
treatment
dmt
ofatumumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410529206.7A
Other languages
English (en)
Chinese (zh)
Inventor
K·拉马纳坦
D·A·赫林
M·巴格
M·梅尔施海姆克
M·齐恩
R·平吉力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72709332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN118436777(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN118436777A publication Critical patent/CN118436777A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410529206.7A 2019-09-11 2020-09-10 通过转换疗法治疗rms Pending CN118436777A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP19196789.2 2019-09-11
EP19196789 2019-09-11
EP20154736 2020-01-30
EP20154736.1 2020-01-30
PCT/EP2020/075332 WO2021048280A1 (en) 2019-09-11 2020-09-10 Treatment of rms by switching therapy
CN202080064158.9A CN114401742B (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080064158.9A Division CN114401742B (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Publications (1)

Publication Number Publication Date
CN118436777A true CN118436777A (zh) 2024-08-06

Family

ID=72709332

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410529206.7A Pending CN118436777A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202080064158.9A Active CN114401742B (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529209.0A Pending CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202080064158.9A Active CN114401742B (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms
CN202410529209.0A Pending CN118403156A (zh) 2019-09-11 2020-09-10 通过转换疗法治疗rms

Country Status (15)

Country Link
US (1) US20220298253A1 (https=)
EP (2) EP4230655A3 (https=)
JP (2) JP7794735B2 (https=)
KR (1) KR20220062025A (https=)
CN (3) CN118436777A (https=)
AU (1) AU2020344154A1 (https=)
CA (1) CA3150947A1 (https=)
DK (1) DK3864053T3 (https=)
ES (1) ES2957112T3 (https=)
FI (1) FI3864053T3 (https=)
IL (1) IL290619A (https=)
LT (1) LT3864053T (https=)
MX (1) MX2022003010A (https=)
SI (1) SI3864053T1 (https=)
WO (1) WO2021048280A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053638A (zh) 2016-08-15 2025-05-30 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法
MX2022003030A (es) * 2019-09-11 2022-04-07 Novartis Ag Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab.
US20230151106A1 (en) * 2020-04-09 2023-05-18 Novartis Ag OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG
US20240228647A1 (en) * 2021-04-14 2024-07-11 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2692343A1 (en) * 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
EA201692180A1 (ru) * 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN120053638A (zh) 2016-08-15 2025-05-30 诺华股份有限公司 使用奥法木单抗治疗多发性硬化的方案和方法

Also Published As

Publication number Publication date
ES2957112T3 (es) 2024-01-11
IL290619A (en) 2022-04-01
EP3864053B1 (en) 2023-07-05
CN114401742B (zh) 2024-05-24
DK3864053T3 (da) 2023-09-11
CN118403156A (zh) 2024-07-30
CA3150947A1 (en) 2021-03-18
CN114401742A (zh) 2022-04-26
SI3864053T1 (sl) 2023-12-29
FI3864053T3 (fi) 2023-09-13
MX2022003010A (es) 2022-06-02
KR20220062025A (ko) 2022-05-13
EP4230655A3 (en) 2023-11-01
JP7794735B2 (ja) 2026-01-06
JP2026016387A (ja) 2026-02-03
EP4230655A2 (en) 2023-08-23
EP3864053A1 (en) 2021-08-18
AU2020344154A1 (en) 2022-04-07
US20220298253A1 (en) 2022-09-22
WO2021048280A1 (en) 2021-03-18
JP2022548575A (ja) 2022-11-21
LT3864053T (lt) 2023-09-11

Similar Documents

Publication Publication Date Title
CN114401742B (zh) 通过转换疗法治疗rms
JP2024156984A (ja) 難治性全身型重症筋無力症の処置のための方法
US20010016195A1 (en) Cytokine antagonists for the treatment of localized disorders
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
Kes et al. Recommendations for diagnosis and management of multiple sclerosis
WO2023144699A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
CA3229704A1 (en) Ofatumumab for treating pediatric ms
JP2026009900A (ja) 血清ＩｇＧを維持しながらＭＳを治療するためのオファツムマブ
RU2849464C1 (ru) Лечение rms путем смены терапии
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
Ryan et al. Providing pharmaceutical care to the multiple sclerosis patient
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
Saeidi et al. Observational Study on the Safety and Efficacy of Rituximab in Multiple Sclerosis: Insights from North-Eastern Iran: Rituximab Efficacy and Safety in MS: Iran
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
Bašić Kes et al. Preporuke za dijagnostiku i liječenje multiple skleroze

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination